Euichaul Oh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6470832/publications.pdf

Version: 2024-02-01

567281 677142 37 600 15 22 h-index citations g-index papers 37 37 37 990 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Investigation of Crystallization and Salt Formation of Poorly Water-Soluble Telmisartan for Enhanced Solubility. Pharmaceutics, 2019, 11, 102.	4.5	15
2	Multivariate Statistical Optimization of Tablet Formulations Incorporating High Doses of a Dry Herbal Extract. Pharmaceutics, 2019, 11, 79.	4.5	7
3	Mesoporous Pravastatin Solid Dispersion Granules Incorporable Into Orally Disintegrating Tablets. Journal of Pharmaceutical Sciences, 2018, 107, 1886-1895.	3.3	5
4	Cell-penetrating peptide-based non-invasive topical delivery systems. Journal of Pharmaceutical Investigation, 2018, 48, 77-87.	5. 3	21
5	Reprecipitation of poorly water-soluble cilostazol crystals using adsorbing carriers for enhanced dissolution and physicochemical modification. Journal of Drug Delivery Science and Technology, 2018, 43, 477-486.	3.0	15
6	pH-independent controlled release tablets containing nanonizing valsartan solid dispersions for less variable bioavailability in humans. Journal of Drug Delivery Science and Technology, 2018, 46, 365-377.	3.0	18
7	Amelioration of high fat diet-induced nephropathy by cilostazol and rosuvastatin. Archives of Pharmacal Research, 2017, 40, 391-402.	6.3	15
8	Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium. International Journal of Pharmaceutics, 2017, 523, 343-356.	5.2	12
9	Consecutive One-Pot versus Domino Multicomponent Approaches to 3-(Diarylmethylene)oxindoles. Molecules, 2017, 22, 503.	3.8	12
10	Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans. Drug Design, Development and Therapy, 2016, Volume 10, 2959-2972.	4.3	3
11	Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1533-1543.	2.0	23
12	Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice. PLoS ONE, 2016, 11, e0150791.	2.5	5
13	Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles. Biomedicine and Pharmacotherapy, 2016, 80, 162-172.	5.6	28
14	In vitro stereoselective inhibition of ginsenosides toward UDP-glucuronosyltransferase (UGT) isoforms. Toxicology Letters, 2016, 259, 1-10.	0.8	24
15	Employing an optimized spray-drying process to produce ezetimibe tablets with an improved dissolution profile. Journal of Pharmaceutical Investigation, 2016, 46, 583-592.	5.3	15
16	Rationale and strategies for formulation development of oral fixed dose combination drug products. Journal of Pharmaceutical Investigation, 2016, 46, 615-631.	5.3	18
17	Effect of biomimetic shear stress on intracellular uptake and cell-killing efficiency of doxorubicin in a free and liposomal formulation. International Journal of Pharmaceutics, 2016, 510, 42-47.	5. 2	11
18	Improving the dissolution rate of a poorly water-soluble drug via adsorption onto pharmaceutical diluents. Journal of Drug Delivery Science and Technology, 2016, 35, 146-154.	3.0	17

#	Article	IF	CITATIONS
19	Beneficial Effects of Sarpogrelate and Rosuvastatin in High Fat Diet/Streptozotocin-Induced Nephropathy in Mice. PLoS ONE, 2016, 11, e0153965.	2.5	28
20	Pharmacokinetic changes of drugs in a rat model of liver cirrhosis induced by dimethylnitrosamine, alone and in combination with diabetes mellitus induced by streptozotocin. Biopharmaceutics and Drug Disposition, 2015, 36, 1-14.	1.9	1
21	Exacerbation of tumor necrosis factor-induced vascular leak syndrome by aging. Biomedicine and Pharmacotherapy, 2015, 74, 133-137.	5.6	O
22	Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate. Drug Design, Development and Therapy, 2015, 9, 3961.	4.3	12
23	New method and characterization of self-assembled gelatin–oleic nanoparticles using a desolvation method via carbodiimide/N-hydroxysuccinimide (EDC/NHS) reaction. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 89, 365-373.	4.3	63
24	Induction of vascular leak syndrome by tumor necrosis factor-alpha alone. Biomedicine and Pharmacotherapy, 2015, 70, 213-216.	5.6	12
25	Micromeritic properties and instrumental analysis of physical mixtures and solid dispersions with adsorbent containing losartan: Comparison of dissolution-differentiating factors. Powder Technology, 2015, 272, 269-275.	4.2	10
26	In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug–drug interactions. Toxicology Letters, 2015, 232, 458-465.	0.8	15
27	Pharmacokinetics of drugs in spontaneously or secondary hypertensive rats. Xenobiotica, 2014, 44, 77-88.	1.1	1
28	A methodological approach for the biomechanical cause analysis of golf-related lumbar spine injuries. Computer Methods in Biomechanics and Biomedical Engineering, 2014, 17, 1801-1808.	1.6	3
29	Coated dextrin microcapsules of amlodipine incorporable into orally disintegrating tablets for geriatric patients. Biomedicine and Pharmacotherapy, 2014, 68, 1117-1124.	5.6	12
30	Kinematic evaluation of movement smoothness in golf: relationship between the normalized jerk cost of body joints and the clubhead. BioMedical Engineering OnLine, 2014, 13, 20.	2.7	39
31	Pharmacokinetics and tissue distribution of ginsenoside Rh2 and Rg3 epimers after oral administration of BST204, a purified ginseng dry extract, in rats. Xenobiotica, 2014, 44, 1099-1107.	1.1	26
32	Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition. Food and Chemical Toxicology, 2014, 68, 117-127.	3.6	25
33	Metabolic Drug-Drug Interaction Potential of Macrolactin A and 7-O-Succinyl Macrolactin A Assessed by Evaluating Cytochrome P450 Inhibition and Induction and UDP-Glucuronosyltransferase InhibitionIn Vitro. Antimicrobial Agents and Chemotherapy, 2014, 58, 5036-5046.	3.2	12
34	Formulation and optimization of spray-dried amlodipine solid dispersion for enhanced oral absorption. Drug Development and Industrial Pharmacy, 2013, 39, 1133-1141.	2.0	27
35	Formulation and evaluation of an alternative triglyceride-free propofol microemulsion. Archives of Pharmacal Research, 2010, 33, 1375-1387.	6.3	15
36	Preformulation Studies on the S-Isomer of Oxybutynin Hydrochloride, an Improved Chemical Entity (ICEâ,,¢). Drug Development and Industrial Pharmacy, 2001, 27, 321-329.	2.0	21

Euichaul Oh

#	Article	IF	CITATIONS
37	Prediction of the Hiestand Bonding Indices of Binary Powder Mixtures from Single-Component Bonding Indices. Pharmaceutical Development and Technology, 1999, 4, 65-70.	2.4	14